Print this page    •   Back to Web version of article

Agreement to Develop Long-Acting Rilpivirine as PrEP

September/October 2013

On 25 September 2013, Janssen announced that it had signed a license agreement with international nonprofit health organisation PATH for early stage research to develop a long acting depot formulation of rilpivirine as a potential pre-exposure prophylaxis (PrEP) against HIV.1

PATH is planning to collaborate with partners including the HIV Prevention Trials Network for future research for these initial phase 2 studies, and this initiative is funded by the Bill & Melinda Gates Foundation.2

Rilpivirine is an NNRTI currently licensed as an oral drug in ARV treatment-naive adults with a viral load less than or equal to 100,000 copies/mL and is coformulated with tenofovir/FTC in the fixed dose combination Eviplera (Edurant in the U.S.).


  1. Jannsen press statement. Janssen R&D Ireland announces agreement with PATH for early development of rilpivirine in long-acting formulation for potential prophylactic intervention, (25 September 2013).
  2. PATH press release. New partnership advances drug formulation that could help prevent HIV infection (25 September 2013).

Links to other websites are current at date of posting but not maintained.

This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. You can find this article online by typing this address into your Web browser:

General Disclaimer: is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.